Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial.
| Field | Value | Language |
| dc.contributor.author | Cromer, Deborah | en_AU |
| dc.contributor.author | Reynaldi, Arnold | en_AU |
| dc.contributor.author | Steain, Megan | en_AU |
| dc.contributor.author | Triccas, James A | en_AU |
| dc.contributor.author | Davenport, Miles P | en_AU |
| dc.contributor.author | Khoury, David S | en_AU |
| dc.date.accessioned | 2022-04-28T02:45:31Z | |
| dc.date.available | 2022-04-28T02:45:31Z | |
| dc.date.issued | 2022 | |
| dc.identifier.uri | https://hdl.handle.net/2123/28443 | |
| dc.description.abstract | The vaccine candidate CVnCoV (CUREVAC) showed surprisingly low efficacy in a recent phase 3 trial compared with other mRNA vaccines. Here we show that the low efficacy follows from the dose used and the presence of SARS-CoV-2 variants, and is predicted by the neutralising antibody response induced by the vaccine. | en_AU |
| dc.language.iso | en | en_AU |
| dc.subject | COVID-19 | en_AUI |
| dc.subject | Coronavirus | en_AUI |
| dc.title | Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial. | en_AU |
| dc.type | Article | en_AU |
| dc.identifier.doi | 10.1093/cid/ciac075 |
Associated file/s
There are no files associated with this item.
Associated collections